Navigation Links
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
Date:10/26/2008

- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs -

NEW HAVEN, Conn., Oct. 26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery, development and commercialization of novel antibiotics for the treatment of antibiotic-resistant infections, today announced positive results from a Phase 2 clinical trial with the oral form of its compound, radezolid (RX-1741), for the treatment of uncomplicated skin and skin structure infections (uSSSI). These results were announced at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th annual meeting (2008 ICAAC/IDSA Joint Meeting) held October 25 - 28 in Washington, D.C.

The open-label trial met both its primary (efficacy) and secondary (safety) endpoints. All doses of radezolid were as efficacious as linezolid (Zyvox(R), currently marketed by Pfizer) and demonstrated a good safety profile. The study also showed that radezolid was approximately four times more potent than linezolid against bacteria cultured from subjects in the study, including against methicillin-resistant Staphylococcus aureus (MRSA), with MIC90s of 0.5mg/L and 2.0mg/L respectively. MIC90s for other relevant bacterial isolates in the study were 0.5mg/L and 2.0mg/L for MRSA and 0.25mg/L and 1.0ug/ml for Streptococcus pyogenes for radezolid and linezolid, respectively. MIC90 is defined as the minimum inhibitory concentration necessary to inhibit the growth of 90 percent of the bacteria.

"We are pleased to report that our novel oxazolidinone, radezolid, may provide a safe and more potent alternative to the only currently marketed drug in this antibiotic class," said Susan Froshauer, PhD, President and CEO of Rib-X Pharmaceuticals. "In particular, radezolid offers a broader spectrum that includes atypicals an
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
2. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
3. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
4. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: ... results for its first quarter ended December 31, 2014. ... 31, 2014, revenue was $1,336,685. Operating expenses were $1,063,393. ... per share.  Covalon,s President and CEO, ... with the significant progress we have made over the ...
(Date:2/27/2015)... SOUTH PLAINFIELD, N.J., Feb. 27, 2015  PTC Therapeutics, ... corporate update and reported financial results for the fourth ... "2014 was a transformative year for PTC. ... on delivering and developing RNA-targeted therapies in the rare ... Officer, PTC Therapeutics, Inc. "We are proud to bring ...
(Date:2/27/2015)... SAN DIEGO , Feb. 27, 2015 /PRNewswire/ ... three-dimensional biology company focused on delivering breakthrough 3D ... , President and Chief Executive Officer, will present ... "We invite you to join us for ... to provide updates on our commercial launch of ...
Breaking Medicine Technology:Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4
... RGEN ) today announced positive results from a Phase ... in patients with bipolar,disorder. This was a multi-center study ... twice a day for six-weeks. Patients in the,RG2417 and ... baseline,with the exception of mania for which the RG2417 ...
... and Major Secondary Endpoints in the Largest ... Date in Psoriatic Arthritis, BOSTON, Nov. 7 ... (SC) injections of golimumab (CNTO 148),experienced significant and ... the disease, according to findings from the largest ...
Cached Medicine Technology:Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder 2Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder 3Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder 4Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 2Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 3Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 4Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 5Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 6Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 7Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 8
(Date:2/27/2015)... Ticket Down announces that Ed Sheeran ... months of 2015. Tickets for his tour have been ... a record pace. , Ed Sheeran 2015 Tour ... Center, Wednesday, May 6, 2015 , 5/7/15, Ed Sheeran Tickets, ... 7, 2015 , 5/9/15, Ed Sheeran Tickets, Tulsa, OK BOK ...
(Date:2/27/2015)... New York, NY (PRWEB) February 27, 2015 ... announces Google Field Trip Days at MoMath, a new collaboration ... trips to the only math museum in North America on ... nearly 400 students in grades 6-8 from seven schools in ... of hands-on activities and learning. , MoMath strives to fulfill ...
(Date:2/27/2015)... 2015 On time and under budget, ... Hospital Joplin. Inside and out, the nearly 900,000-square-foot facility ... to replace the tornado-ravaged St. John’s Regional Medical Center ... is opening just 46 months after the tornado hit ... normally anticipate to plan, design and construct a similarly ...
(Date:2/27/2015)... FL (PRWEB) February 27, 2015 Local lice ... the rise, particularly in the areas of Pinecrest, Key Biscayne, ... frantic and frustrated as they attempt to isolate and eradicate ... that the common “selfie” photograph may be partly to blame. ... create the kind of head-to-head contact that can allow for ...
(Date:2/27/2015)... Burien Nursing and Rehabilitation Center was ... with the Facility of the Year award. This award ... quality of care / satisfaction, census development, employee satisfaction ... to attend the awards banquet held in Dana Point, ... receive this award on behalf of our team at ...
Breaking Medicine News(10 mins):Health News:Ed Sheeran Tickets at the Hollywood Bowl, Verizon Theatre, The Mann Center, Darlings Waterfront Pavilion, Moda Center, BOK Center, Consol Energy & Red Rocks Now On Sale 2Health News:Ed Sheeran Tickets at the Hollywood Bowl, Verizon Theatre, The Mann Center, Darlings Waterfront Pavilion, Moda Center, BOK Center, Consol Energy & Red Rocks Now On Sale 3Health News:Ed Sheeran Tickets at the Hollywood Bowl, Verizon Theatre, The Mann Center, Darlings Waterfront Pavilion, Moda Center, BOK Center, Consol Energy & Red Rocks Now On Sale 4Health News:National Museum of Mathematics and Google Collaborate to Offer Cost-Free Field Trip Days for Title I Schools in NYC 2Health News:National Museum of Mathematics and Google Collaborate to Offer Cost-Free Field Trip Days for Title I Schools in NYC 3Health News:New Hospital Built to Stand Against Nature 2Health News:New Hospital Built to Stand Against Nature 3Health News:New Hospital Built to Stand Against Nature 4Health News:Parents frustrated as selfies continue to contribute to the spread of head lice in Miami according to the largest Lice Removal Service in Miami called Lice Troopers 2Health News:Burien Nursing and Rehabilitation Center Receives Top Honors with Facility of the Year Award 2Health News:Burien Nursing and Rehabilitation Center Receives Top Honors with Facility of the Year Award 3
... from the University of Alabama at Birmingham (UAB) ... common anti-HIV drugs can prevent HIV-positive pregnant women ... drugs, potentially improving future treatment options., Providing tenofovir ... the extent of resistance to non-nucleoside reverse transcriptate ...
... footwear works best , , FRIDAY, Nov. 9 (HealthDay News) -- ... flexible walking shoes than with other types of footwear, ... the better for the knees, the study finds. , "The ... affects your feet but can affect other joints at your ...
... Girls on the Run-Chicago, CHICAGO, Nov. 9 Get ... more with all the auction items offered for,sale at this ... the,Chicago Cultural Center. The annual event, which attracts more than ... cocktails, hors d,oeuvres and plenty of fun--all for a great ...
... Babies driving robots.,It sounds like the theme ... the focus,of important and innovative research being conducted ... repercussions for the cognitive,development of infants with special ... (Cole) Galloway, associate professor of,physical therapy, and Sunil ...
... As part of the Company,s,commitment to encourage ... support today for the amendment to the Farm ... in schools proposed by Senate,Agriculture Committee Chairman Tom ... US applauds Senators Harkin and Murkowski for championing ...
... Consumers Union finds up to $1,900 annual increases in ... during Nov. 15 open,enrollment period, WASHINGTON, Nov. 9 ... shopping during open enrollment could be,in for a nasty ... year for,premiums and five commonly used prescriptions -- the ...
Cached Medicine News:Health News:HIV drug resistance risk in mothers reduced by combination of common drugs 2Health News:Close to Barefoot Best for Arthritic Knees 2Health News:Close to Barefoot Best for Arthritic Knees 3Health News:Close to Barefoot Best for Arthritic Knees 4Health News:Chicago's Premier Sports and Fitness Auction is Back! 2Health News:Babies Driving Robots at University 2Health News:Babies Driving Robots at University 3Health News:Babies Driving Robots at University 4Health News:Babies Driving Robots at University 5Health News:Babies Driving Robots at University 6Health News:Mars US Supports Harkin/Murkowski Amendment to Update Nutrition Standards for Foods Sold in Schools 2Health News:Cha-Ching! Seniors Enrolled in Medicare Prescription Drug Plans Might Be in for Sticker Shock Next Year 2Health News:Cha-Ching! Seniors Enrolled in Medicare Prescription Drug Plans Might Be in for Sticker Shock Next Year 3Health News:Cha-Ching! Seniors Enrolled in Medicare Prescription Drug Plans Might Be in for Sticker Shock Next Year 4
Used for stone manipulation and removal in the renal pelvis under direct vision. Supplied sterile in peel-open packages. Intended for one-time use....
... is designed to provide rapid atraumatic stone ... NCircle combines traditional surgical instrument design with ... technology. The small, flexible wire design ... surgeon to remove larger stones or stone ...
... Used for temporary internal drainage ... bladder. Supplied sterile in peel-open packages. ... evaluation is advised; C-Flex® and Sof-Flex® ... than six (6) months; silicone stents ...
... ACMI™ Classic Double Pigtail Ureteral Stents ... design that maximizes migration. They also ... versatility and cost savings. Each Classic ... one Classic Double PigTail Ureteral Stent ...
Medicine Products: